The Basham Lab conducts scientific research that contributes to the understanding of how cancer begins in order to develop new therapeutic strategies. We are committed to creating an inclusive and collaborative laboratory environment that advances the training and career development of all members.
The primary focus of our laboratory's research is examining how cells modulate their behavior in response to both extrinsic and intrinsic signals. This process of signal integration has profound effects on cell migration, morphology, and function—behaviors that, when aberrant, can lead to cancer and other diseases.
We are interested in the molecular logic of totipotency—the ability of germ line stem cells and early embryos to become any type of cell. Within this broad and important question, we focus on how chromatin structure and epigenetics helps regulate gene transcription in the germ line and early embryos. We also examine how chromatin/epigenetics is misregulated in cancers.
The main focus of research in the Camp Lab is the identification of germ-line genetic variants that increase susceptibility to disease, with specific interests in breast cancer, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
For decades, geneticists working in Utah have made seminal contributions to the field of cancer predisposition genetics. In late 2019, the creation of the Center for Cancer Genetics (C4CG) at Huntsman Cancer Institute continues our leadership through comprehensive translation of cancer susceptibility gene discoveries to the clinic and to the population.
The Center for Health Outcomes and Population Equity (HOPE) serves as an infrastructure and bridge between scientists and community organizations (e.g., health care, government, education, nonprofits, faith based, social services, tribal) throughout Utah and the Mountain West.
The Chandrasekharan Lab’s focus is to understand the regulation and functions of epigenetic histone modifications and protein homeostasis (proteostasis) mechanisms during gene regulation and genome maintenance, and their therapeutic targeting in cancers.
The Curtin Group has a broad range of research interests which include age-related macular degeneration and co-segregating diseases, epigenetics in cancer, cancer epidemiology with emphasis on colorectal cancer, environmental pollution, and gene-environment interaction.
Melanoma is the most serious form of skin cancer, given its propensity to metastasize. Our work is focused on understanding how particular genes promote (or inhibit) the development and progression of melanoma and to use this knowledge to develop novel strategies for reducing melanoma risk in susceptible individuals.
Our laboratory focuses on understanding mechanisms of cancer progression and developing clinical interventions. Our goals are to 1) uncover novel mechanisms of tumorigenesis and metastasis, 2) identify biomarkers that prognosticate disease progression or predict treatment response and 3) collaborate with industry to develop new therapies for the prevention and treatment of cancer progression.
Dr. Hu-Lieskovan’s laboratory uses cutting-edge technologies to investigate mechanisms of resistance to immunotherapy, develop novel combination strategies to overcome resistance, improve efficacy, and monitor and prevent immunotherapy-induced toxicities.
The Skyler Johnson Research Lab is focused on health services research, specifically cancer patient treatment decision making, cancer misinformation, alternative and complementary treatment use, cancer outcomes, and survivorship.
The Judson-Torres Lab investigates how the interplay between the initial transcriptional state of a normal cell, acquired genetic mutations, and extracellular signaling contributes to cancer initiation and progression.
The K. B. Jones Lab is directed by and supports Dr. Jones as he provides care to patients of all ages with bone and soft-tissue sarcomas, performing surgery to remove the cancers and reconstruct the limbs or body wall.
The Kepka group is engaged in population science research that addresses health disparities related to cancer risk in vulnerable populations. Our goals are to drive quality improvement and increase access to primary health care services for cancer prevention and control among minority and underserved populations.
The Mendoza Lab is using recent advances in proteomics and quantitative imaging to understand how extracellular signals impinge on cytoskeletal dynamics and how oncogenic pathway hyperactivation impacts cancer invasion.
The Mooney lab focuses on research that links cancer control with behavioral science. We work to understand and reduce cancer morbidity and use that understanding to develop treatments for related physical and psychosocial symptoms. Our intent is to improve patient-reported outcomes (PROs).
In multicellular organisms, cell-cell communication is tightly controlled to ensure proper development and prevent diseases such as cancer. Our lab studies a key aspect of this process: how extracellular signals are transmitted across the membrane to the cell interior.
The Suneja Lab seeks to ensure the highest quality cancer care is accessible and equitably delivered to all patients. Current areas of focus include disparities in cancer treatment and outcomes in people with HIV, radiation oncology workforce diversity, short course gynecologic radiotherapy, impact of COVID on cancer treatment in vulnerable populations, and HIV-mediated differences in tumor microenvironments.
Research in the Tavtigian Lab concentrates on two areas of genetic susceptibility to cancer: 1) Identification and characterization of intermediate-risk and high-risk cancer susceptibility genes, and 2) analysis of unclassified variants that are observed during the clinical testing of established high-risk cancer susceptibility genes.
The Ulrich Group investigates genetic and lifestyle factors in the formation and prognosis of cancer with focus on colorectal cancer. In addition Dr. Ulrich focuses on prevention strategies with NSAIDs, with pharmacogenetics, nutrition, exercise and cancer, as well as connections between obesity, adipose tissue, and the progress of cancer.
The VanBrocklin Lab is interested in identifying novel molecular targets vital for tumor growth and progression and validating these candidates in pre-clinical models in order to develop rational pharmacological intervention strategies for melanoma and NSCLC patients